
Myriad Genetics (MYGN) has announced Ben Wheeler's promotion to Chief Financial Officer, effective August 16, 2025, succeeding Scott Leffler who will serve as a consultant through September 2. Wheeler, an internal candidate with over 13 years at the company and previously CFO of operations, brings continuity to the finance function. Notably, Myriad concurrently reaffirmed its full-year financial outlook, indicating no change in its guidance despite the leadership transition.
Myriad Genetics (MYGN) has announced a planned and orderly CFO succession, promoting internal candidate Ben Wheeler to the role effective August 16, 2025. Wheeler's long tenure of over 13 years with the company, most recently as CFO of Operations, signals a commitment to strategic continuity and minimizes the disruption typically associated with C-suite changes. The transition is further smoothed by the outgoing CFO, Scott Leffler, remaining as a consultant. Critically, the company concurrently reaffirmed its full-year financial outlook, which was issued on August 5. This action explicitly decouples the leadership change from any alteration in near-term business performance expectations, providing a key stabilizing signal to the market. The extended timeline for the transition underscores a deliberate and well-managed succession process, rather than a reaction to any immediate operational or financial issues.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment